This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/2/2021
Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals conference call to discuss the company's operations and third quarter 2021 financial results. My name is Tina, and I'll be your operator for today's call. At this time, all participant lines are in a listen-only mode. There will be a question and answer session at the end to follow. Please be advised that this call is being recorded at Infinity's request. Now, I would like to introduce your host for today's call, Jane Kaufman. Please go ahead.
Jane Kaufman Thank you, Tina, and good afternoon, everyone. Welcome to today's call to discuss our recent business progress and review of our third quarter 2021 financial results. On the call with me today are Adeline Perkins, Chief Executive Officer, Larry Block, President, Robert Ilaria, Chief Medical Officer, and Stephon Caluso, Chief Scientific Officer. We'll open up the call for Q&A following our remarks. The press release issued this afternoon details our results and is available on our website at INFE.com. Please note that during this call, we may make forward-looking statements about our future expectations and plans, including clinical development objectives, the therapeutic potential of our product candidates, our strategic plans and strategies, and financial projections. Our actual results may differ materially from what we project today. due to a number of important factors, including the considerations described in the risk factor section of our annual report on Form 10-K for 2020 and in other filings we make with the FCC. These forward-looking statements represent our views only as of today, and we caution you that we may not update them in the future, whether as a result of new information, future events, or otherwise. Now, I'd like to turn the call over to Adeline.
Thanks, Jane. And thank you to everyone for joining us today. This is a very important time at Infinidate as we focus on three significant value drivers for the company. First, our evolving clinical and translational data, which we will review during today's call, suggests we have a drug with the Ganylysin and lay the foundation for significant additional value creation. Second, based on these data, we are making the very important transition from seeking proof of concept with aganalysib to advancing a registration-focused study. Third, our validation of aganalysib's unique mechanism of action in reprogramming macrophages substantiates aganalysib's potential beyond TNBC and urothelial cancer. Aganalysib is distinctively well-positioned as the only PI3 kinase gamma inhibitor in clinical development to drive differentiated benefits for patients. In particular, we have shown the ability of aganalysib to improve the outcomes of its combination drug partners, particularly checkpoint inhibitors, which have historically benefited a minority of treated patients and which are increasingly dependent upon complementary combinations to improve results. I'll now elaborate on each of these three value drivers. starting with data. Last quarter, we presented data in patients with second-line metastatic urothelial cancer and in patients with first-line metastatic triple-negative breast cancer, which provides compelling evidence that aganalysib improves patient outcomes. Importantly, we are seeing this evidence on the most meaningful metrics of patient benefit, namely prolonged progression-free survival, or PFS, and extended overall survival, or OS, and we see these benefits for patients regardless of their baseline PD-L1 status. We are very pleased to have been invited to present updated TNBC data at the 2021 San Antonio Breast Cancer Symposium this December. As our TNBC data mature, we are especially interested in confirming whether the PFS results from this summer, which exceeded our expectations, are maintained over a longer period of time in more patients. Prolonged PFS is particularly meaningful for PD-L1 negative metastatic frontline TNBC patients for whom no checkpoint inhibitors have been approved, which leads me to our second value driver as we turn our attention to registration enabling studies. The strength of the PFS and OS data we have generated in TNBC and UC is particularly relevant is these are likely to be the primary endpoints for potential registration trials. We are actively engaged with key opinion leaders and regulatory authorities in the design of a registration-focused study in UC, and the strength of our PFS and OS data gives us confidence in our ability to meet the high bars necessary for approval. We look forward to updating you on our plans for GAN-ELICIB in UC on January 5th in conjunction with our 2022 guidance. Our UC, PFS, and OS data are further bolstered by translational evidence from biopsies indicating that there is significantly greater immune activation in the treatment arm with aganalysin versus the control arm without aganalysin. So the drug is doing exactly what it was designed to do, which brings me to our third value driver, which is the breadth of aganalysip's potential beyond TNDC and UC. Over the past 12 months, we have shown very encouraging clinical and translational data on aganalysip activity relative to reference benchmarks across five different tumor types, three different combination regimens, and in multiple lines of therapy, all of which demonstrate aganalysip's power to activate an immune response. The data from each of these individual studies alone is notable, and becomes even more compelling when viewing the totality of the data, where its consistency across multiple settings underscores the potential of aganalysib to drive the next generation of immuno-oncology therapies. This is particularly true given that aganalysib is the only PI3 kinase gamma-specific inhibitor in clinical development. The only way to access the unique macrophage reprogramming achieved through inhibition of PI3 kinase gamma is with aganalysib. There is no alternative PI3 kinase gamma inhibitor in the clinic, so as our clinical data mature favorably, the scarcity value of aganalysib increases dramatically, as does the attractiveness of our strategic options. Hence, our highest priority is to advance the three value drivers outlined above. by continuing to generate strong clinical and translational data, advance registration-enabling studies, and leverage the fundamental biologic mechanism of EGAN-ELICIT in remodeling the tumor microenvironment to improve patient outcomes across additional settings. To achieve this, we have further strengthened our clinical and scientific leadership, as well as our board of directors. Last quarter, we announced the appointment of our chief scientific officer Dr. Stephan Peluso, who, with prior experience at Infinity, is uniquely qualified and ideally positioned to push forward the important scientific work that is the foundation of our program. On the clinical front, we have appointed a new chief medical officer to succeed Dr. Brian Schwartz, who served as our consulting chief physician and made impactful contributions in guiding our clinical programs through key data readouts that paved the way for the ongoing development of Eganilisib. We could not be more pleased that Brian is continuing to contribute to INFINITY and Eganilisib from his new position on our board. We are thrilled that Dr. Robert Aloria has joined INFINITY as our chief medical officer to lead the future clinical development of Eganilisib. Rob brings an ideal background to INFINITY given his deep expertise in drug development in immuno-oncology. He joins us from BMS and Cellgene, where he led BMS's CTLA-4 program and Celgene's PD-1 inhibitor program in collaboration with BiGene. Rob's strong track record in drug development from preclinical through approval during his tenure at Lilly, Celgene, and BMS is critical to the top value drivers I just reviewed. Throughout his pharma career, and now at Infinity, Dr. Ilaria has continued to treat patients, including for some of the indications for which we are now evaluating Eganilisib, including TNBC, such that he is acutely aware of the magnitude of the need for those patients. With that, I'll turn the call over to Rob. Rob?
You're reading a preview of the INFI Q3 2021 earnings call.
Free account.
